Anti-angiogenic therapy follow-up in mice brain glioma model with P04000, a new molecular imaging avb3-nanoemulsion of iron oxide.

A new iron oxide nanoparticle based USPIO (P04000) is evaluated in terms of specificity and capacity to monitor antiangiogenic treatment in a brain tumor model in mice. The high affinity rgd vectored contrast agent who targets avb3 allows, with a basic Multi Gradient Echo sequence, to specifically enhance the tumor 2 hours post injection. The uptake of this agent is reduced to zero in the bevacizumab treated group before the tumor regression. This MR contrast agent is able to early demonstrate the effect of anti-angiogenic therapy with feasible MRI sequence and data post processing in humans.

How to access this content:

For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.

After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.

After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.

Click here for more information on becoming a member.